Table 2.

Treatment-related adverse events.

		n = 50
Anti-PD-1 inhibitor-related AEs	Any grade	Grade 1–2	Grade 3–4
Discontinued due to AEs	4 (8)	1 (2)	3 (6)
Fatigue	17 (34)	17 (34)	0
Transaminitis	10 (20)	10 (20)	0
Fever	8 (16)	8 (16)	0
Diarrhea	6 (12)	6 (12)	0
Pneumonitis	5 (10)	4 (8)	1 (2)
Hyperbilirubinemia	4 (8)	2 (4)	2 (4)
Hypothyroidism	4 (8)	3 (6)	1 (2)
Pruritus	4 (8)	4 (8)	0
Rash	4 (8)	4 (8)	0
Hyperthyroidism	3 (6)	3 (6)	0
Hypoalbuminemia	3 (6)	3 (6)	0
Hypoleukemia	3 (6)	2 (4)	1 (2)
Thrombocytopenia	3 (6)	2 (4)	1 (2)
Prolactin increase	2 (4)	2 (4)	0
Alopecia	1 (2)	1 (2)	0
Anemia	1 (2)	1 (2)	0
Appetite decrease	1 (2)	1 (2)	0
Creatinine increase	1 (2)	1 (2)	0
Diabetic metabolic decompensation	1 (2)	1 (2)	0
Nausea	1 (2)	1 (2)	0
		n = 47 *
Ablation-related complications	Any	Grade A-B	Grade C-D
Discontinued due to complications	0	0	0
Pain	47 (100)	41 (87.2)	6 (12.8)
Transaminitis	19 (40.4)	10 (21.3)	9 (19.1)
Vomiting	22 (46.8)	22 (46.8)	0
Constipation	13 (27.7)	13 (27.7)	0
Fever	11 (23.4)	11 (23.4)	0
Intraabdominal hemorrhage	11 (23.4)	9 (19.1)	2 (4.3)
Pneumothorax	7 (14.9)	5 (10.6)	2 (4.3)
Pleural effusion	9 (19.1)	7 (14.9)	2 (4.3)
Bile duct pneumatosis	6 (12.8)	6 (12.8)	0

Data are n (%), unless otherwise indicated.

^*A total of 47 times of ablation procedures were performed in 33 patients.

AEs, adverse events; PD-1, programmed cell death protein-1.